Findings

What do systematic reviews say?

1 questions · 3 findings · 1 reviews · Haematology

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 0 · 0%High 1 · 33.3%

Thrombocytopenia · All patients with a diagnosis of multiple myeloma

Bortezomib may leads to higher adverse Events: Thrombocytopenia compared with no bortezomib (low certainty).

3 findings from 1 review

Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
OR 2.05 [1.7, 2.48]
8 studies · 3791 participants
Low
Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
OR 1.51 [1.13, 2]
3 studies · 1196 participants
High
Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
OR 2.6 [2.01, 3.35]
5 studies · 2595 participants
Low